Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy.

AIM: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of posttreatment growth on AH.

STUDY

DESIGN

Medical records of girls with CPP were reviewed.

RESULTS

Twenty-six girls aged 7.2 +/- 2.0 years were identified. There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005). Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy. Growth after discontinuation of therapy was variable and often greater than expected. Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth.

CONCLUSION

This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa. The lack of predictability of growth after discontinuation of therapy suggests that the decision to stop treatment should be individualized.